These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

415 related items for PubMed ID: 29945962

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer.
    Liu SS, Li Y, Zhang H, Zhang D, Zhang XB, Wang X, Yu Y.
    Theranostics; 2020; 10(23):10729-10742. PubMed ID: 32929377
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer.
    Liu J, Li X, Wang M, Xiao G, Yang G, Wang H, Li Y, Sun X, Qin S, Du N, Ren H, Pang Y.
    Int J Oncol; 2018 Oct; 53(4):1601-1612. PubMed ID: 30066905
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. MiR-873 regulates ERα transcriptional activity and tamoxifen resistance via targeting CDK3 in breast cancer cells.
    Cui J, Yang Y, Li H, Leng Y, Qian K, Huang Q, Zhang C, Lu Z, Chen J, Sun T, Wu R, Sun Y, Song H, Wei X, Jing P, Yang X, Zhang C.
    Oncogene; 2015 Jul 23; 34(30):3895-907. PubMed ID: 25531331
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. ObRb downregulation increases breast cancer cell sensitivity to tamoxifen.
    Qian Y, Shi D, Qiu J, Zhu F, Qian J, He S, Shu Y, Yin Y, Chen X.
    Tumour Biol; 2015 Sep 23; 36(9):6813-21. PubMed ID: 25846733
    [Abstract] [Full Text] [Related]

  • 15. MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.
    Ward A, Shukla K, Balwierz A, Soons Z, König R, Sahin O, Wiemann S.
    J Pathol; 2014 Aug 23; 233(4):368-79. PubMed ID: 24752803
    [Abstract] [Full Text] [Related]

  • 16. Wilms' tumor 1 suppressor gene mediates antiestrogen resistance via down-regulation of estrogen receptor-alpha expression in breast cancer cells.
    Han Y, Yang L, Suarez-Saiz F, San-Marina S, Cui J, Minden MD.
    Mol Cancer Res; 2008 Aug 23; 6(8):1347-55. PubMed ID: 18708366
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Aberrant expression of SETD1A promotes survival and migration of estrogen receptor α-positive breast cancer cells.
    Jin ML, Kim YW, Jin HL, Kang H, Lee EK, Stallcup MR, Jeong KW.
    Int J Cancer; 2018 Dec 01; 143(11):2871-2883. PubMed ID: 30191958
    [Abstract] [Full Text] [Related]

  • 19. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
    Basak P, Chatterjee S, Bhat V, Su A, Jin H, Lee-Wing V, Liu Q, Hu P, Murphy LC, Raouf A.
    Cell Physiol Biochem; 2018 Dec 01; 51(4):1518-1532. PubMed ID: 30497079
    [Abstract] [Full Text] [Related]

  • 20. miR-191/DAB2 axis regulates the tumorigenicity of estrogen receptor-positive breast cancer.
    Tian X, Zhang Z.
    IUBMB Life; 2018 Jan 01; 70(1):71-80. PubMed ID: 29247596
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.